80.53MMarket Cap-673P/E (TTM)
1.370High1.340Low11.12KVolume1.340Open1.340Pre Close14.93KTurnover0.03%Turnover RatioLossP/E (Static)60.09MShares2.09052wk High0.59P/B57.25MFloat Cap0.69052wk Low--Dividend TTM42.72MShs Float39.605Historical High--Div YieldTTM2.25%Amplitude0.690Historical Low1.342Avg Price1Lot Size
Kronos Bio Stock Forum
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provi...
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
• $Cogent Biosciences(COGT.US)$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US)$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US)$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US)$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
No comment yet